Remdesivir-Induced Hepatotoxicity: A Systematic Review of Clinical Evidence, Pharmacokinetics, and Safety Concerns
), Muhamad Begawan Bestari(2), Dolvy Girawan(3), Nenny Agustanti(4), Okky Husain(5), Nadeem S. Hasan(6),
(1) Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran
(2) Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran
(3) Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran
(4) Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran
(5) Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran
(6) King Faisal Specialist Hospital & Research Center, Madinah Munawwarah, Saudi Arabia
Corresponding Author
Abstract
Background: Remdesivir is widely used for the treatment of COVID-19, with its potential benefits currently under investigation. Concerns remain regarding its potential hepatotoxic side effects. Drug-drug interactions, specifically with CYP3A4 and P-glycoprotein inhibitors, may worsen hepatotoxicity. In this context, dexamethasone has been suggested to mitigate liver injury, but the role remains unclear. Therefore, this study aimed to explore the characteristics, mechanisms, and risk factors of remdesivir-induced hepatotoxicity through a systematic review of case reports.
Methods: A systematic review was conducted using databases such as PubMed, Scopus, EBSCO, and BMJ Case Reports for cases published from 2020 to 2024. The keywords used were “remdesivir,” “hepatotoxicity,” “COVID-19,” and “liver failure.” Relevant case reports were selected based on predefined inclusion and exclusion criteria. Furthermore, data were extracted following the Joanna Briggs Institute (JBI) checklist for case reports.
Results: Among 46 individual articles screened after the removal of duplicates, five that detailed a total of six patients were eligible for inclusion. Hepatotoxicity was frequently reported in elderly patients and those with chronic liver disease. Drug-drug interactions that include remdesivir and CYP3A4 inhibitors increased the risk of liver injury. Based on observation, dexamethasone was associated with reduced hepatotoxicity, primarily due to its anti-inflammatory effects. In patients with ALT >5× ULN, remdesivir administration was controversial. Some cases showed improvement, and others required discontinuation due to severe liver dysfunction.
Conclusion: This study emphasized the necessity for safety evaluations and standardized liver function monitoring in patients receiving remdesivir. Further investigation is essential to define clinical guidelines and improve patient safety in antiviral treatments.
Keywords
References
The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N ENGL J MED. 2021;384(8).
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020;11(222):1-14.
Howard BJ, Marie TK, Kumar DLEMA, Yvonne ZBSKACHECH. Remdesivir for the Treatment of Covid-19 — Final Report. n engl j med. 2020;383(19):1813-26.
Burhan E, Syahruddin E, Isbaniah F, Desianti GA, Fachrucha F, Sari CYI, et al. Evaluation of the safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study. Frontiers in Pharmacology. 2023;14.
Kausar S, Khan FS, Rehman MIMU, Akram M, Riaz M, Rasool G, et al. A review: Mechanism of action of antiviral drugs. International Journal of Immunopathology and Pharmacology. 2021;35:1-12.
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clinical Microbiology Reviews. 2021;34(1).
Lin Y, Weynand B, Zhang X, Jochmans MLD, Neyts J. The Combination of GS-441524 (Remdesivir) and Ribavirin Results in a Potent Antiviral Effect Against Human Parainfluenza Virus 3 Infection in Human Airway Epithelial Cell Cultures and in a Mouse Infection Model. Viruses. 2025;17(2):172.
Shamsher E, Dash J, Serratrice J, Coen M, Zacharias-Fontanet A, Laubscher F, et al. Imported severe West Nile virus neuro-invasive disease treated by remdesivir in a patient with anti-CD20 therapy for multiple sclerosis: A case report. CMI Communications. 2024;1(2).
Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2021;50.
Thakare S, Gandhi C, Deb TMSBS, Katyal NSA, Patil APS, Pajai A. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep. 2020;6:206-10.
Ravari AF, Malakouti M. Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19. Pharmacoepidemiology. 2024;3(1):69-81.
Kim MS, Jung SY, Lee SW, Li H, Koyanagi A, Kronbichler A, et al. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study. Clinical Gastroenterology and Hepatology. 2021;19:1970-2.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020;18(10):2127-33.
Ahmed-Khan MA, Matar G, Coombes K, Moin K, Joseph BM, Funk CM. Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review. Cureus. 2023;15(1).
Leegwater E, Strik A, Wilms EB, Bosma LBE, Burger DM, Ottens TH, Nieuwkoop Cv. Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors. Clinical Infectious Diseases. 2020;72(7):1256-8.
Dividis GP, Papadopoulos GE, Karageorgiou I, Kotronis G. Remdesivir Induced Liver Injury in a Patient with Coronavirus Disease 2019 and History of Congestive Hepatopathy. Cureus. 2022;14(12).
Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. PHARMACOTHERAPY. 2020;40(11).
Sabers AJ, Farley ALWTM. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. BMJ Case Rep. 2020;13.
Tolou-Ghamari Z. Remdesivir: A Quick Review of Pharmacotherapy. New Emirates Medical Journal. 2024;5.
Deb S, Reeves AA, Hopefl R, Bejusca R. ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. pharmaceuticals. 2021;14:655.
Zhang RX, Dong K, Wang Z, Miao R, Lu W, Wu XY. Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine. Pharmaceutics. 2021;13:1261.
Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, et al. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Frontiers in Pharmacology. 2022;13.
Dreshaj A, Dreshaj A, Sinanaj D, Morina E, Dehari S. Main consequences of enzymatic induction and inhibition during the interaction of drugs and the role of CYP3A4, CYP3A45 enzymes. Curr Issues Pharm Med Sci. 2023;37(1):1-6.
Pedraza L, Laosa O, Rodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, Ramírez E. Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. Frontiers in Pharmacology. 2021;11.
Chalasani N, Bonkovsky H, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and Outcomes of 899 Patients with Drug-induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015;148(7):1340–52.
Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver International. 2022;42:1999–2014.
Hua X, Sunb L, Guoa Z, Wud C, Yuc X, Lia J. Management of COVID-19 patients with chronic liver diseases and liver transplants. Annals of Hepatology. 2022;27.
Deb S, Reeves AA. Simulation of Remdesivir Disposition and Its Drug Interactions. J Pharm Pharm Sci. 2021;24:277-91.
Ling SY, Huizinga RB, Freitag PRMRLDG, Foster LJART. Cytochrome P450 3A and P-glycoprotein drug–drug interactions with voclosporin. British Journal of Clinical Pharmacology. 2013;77(6):1039-50.
Ershad M, Naji A, Patel P, Vearrier D. N-Acetylcysteine: StatPearls Publishing; 2024.
Fisher ES, Curry SC. Evaluation and treatment of acetaminophen toxicity. Adv Pharmacol. 2019;85:263-72.
Lee WM, Stravitz RT, Larson AM. Introduction to the Revised American Association for the Study of Liver Diseases Position Paper on Acute Liver Failure 2011. Hepatology. 2012;55(3):965–7.
Amjad W, Thuluvath P, Dutta MMA, Ali F, Qureshi W. N-acetylcysteine in non-acetaminophen-induced acute liver failure: a systematic review and meta-analysis of prospective studies. Prz Gastroenterol. 2021;17(1):9-16.
Popescu M, Bratu A, Sima MATBMJR-M, Orban C. The Use and Potential Benefits of N-Acetylcysteine in Non-Acetaminophen Acute Liver Failure: An Etiology-Based Review. Biomedicines. 2024;12(3):676.
Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, et al. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. Clinical Infectious Diseases. 2021;73(9):e3377–e83.
Jawaid H, Ali MM, Khan MU, Sami S, Shaikh MA. Efficacy and safety of N-acetylcysteine for the treatment of non-acetaminophen-induced acute liver failure: an updated systematic review and meta-analysis. Clin Exp HEPATOL. 2021;7(2):156–64.
Liu K, Stern S, Heil EL, Li L, Khairi R, Heyward S, Wang H. Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients. Hepatology Communications. 2023;7.
Björnsson ES, Vucic V, Stirnimann G, Robles-Díaz M. Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. Frontiers in Pharmacology. 2022;13.
Niu H, Ma J, Medina-Caliz I, Robles-Diaz M, Bonilla-Toyos E, Ghabril M, et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023;57:886-96.
Zhang R, Yang QWJ. Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment. J Clin Transl Hepatol. 2022;10(4):748–56.
Article Metrics
Abstract View
: 327 times
Download : 122 times
DOI: 10.24871/2632025228-236
Refbacks
- There are currently no refbacks.
